Ketamine Treatment of Youth Suicide Attempters
NCT04763343 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60
Last updated 2026-03-20
Summary
Ketamine, an NMDA antagonist, has been shown to have rapid anti- suicidal effects. However, its safety and efficacy and special populations has not been investigated and documented. Several reports in adults suggest rapid decrease of suicidal ideation. In the last decade there is an alarming increase of the number of suicide attempts in patients ages 14-30. Suicide is the second leading cause of death in this population. Patients with previous history of suicide attempt, are even in a higher risk category. The present study focus in this high risk group of suicide attempters. This will be a randomized controlled trial enrolling 60 youth between the ages 14-30 after a suicide attempt; patients will be randomized to receive Ketamine 0.5 mg/kg over 40 minutes or normal saline. Patients will receive all Ketamine or placebo infusions while admitted in the Inpatient Psychiatry Service. Patients will receive up to 6 ketamine or placebo infusions until, for 3 consecutive sessions, they have a clinician rated Scale for Suicidal Ideation (SSI) score of\<4, and \>50% decrease from baseline, and clinical assessment of patient not being suicidal, or they have been discharged from the inpatient unit. Patients will participate in weekly sessions of Collaborative Assessment for the management of Suicidality (CAMS), from the first week of the study while admitted to the hospital and will continue it on a weekly basis post-discharge until the patient has three consecutive outpatient CAMS sessions with an overall risk \< 2 (# 6 on the SSF Core Assessment) along with a positive response regarding their thoughts/feelings and clinician indicating behavioral stability (suicidal behavior).
Conditions
- Suicide, Attempted
Interventions
- DRUG
-
Ketamine Hydrochloride
Ketamine hydrochloride will be given as an intravenous infusion using a standard regimen given in most studies conducted: 0.5 mg/kg over 40 minutes. Ketamine infusions will be given every other day until either the subject reports clinician rated Scale for Suicidal Ideation (SSI) score of\<4, and \>50% decrease from baseline, and clinical assessment of patient not being suicidal for three consecutive pre-infusion ratings, or a maximum of six infusions have been given over the course of 2 weeks, or they have been discharged from the inpatient unit.
- DRUG
-
Saline
Subjects randomized to placebo will be administered a saline (0.9% sodium chloride) drip for 40 minutes. Saline placebo infusions will be given every other day until either the subject reports clinician rated Scale for Suicidal Ideation (SSI) score of\<4, and \>50% decrease from baseline, and clinical assessment of patient not being suicidal for three consecutive pre-infusion ratings, or a maximum of six infusions have been given over the course of 2 weeks, or they have been discharged from the inpatient unit.
- BEHAVIORAL
-
CAMS Therapy
CAMS weekly sessions will also be started immediately as an inpatient at the start of the study while receiving ketamine or saline. CAMS will be continued weekly after the patient is discharged and followed up as an outpatient. Weekly CAMS sessions will be terminated after the subject, as an outpatient, has three consecutive outpatient CAMS sessions with an overall risk \< 2 (# 6 on the SSF Core Assessment) along with a positive response regarding their thoughts/feelings and clinician indicating behavioral stability (suicidal behavior).
Sponsors & Collaborators
-
National Institutes of Health (NIH)
collaborator NIH -
National Institute of Mental Health (NIMH)
collaborator NIH -
Massachusetts General Hospital
collaborator OTHER -
Tatiana Falcone, MD
lead OTHER
Principal Investigators
-
Tatiana Falcone, M.D. · The Cleveland Clinic
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 14 Years
- Max Age
- 30 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-06-27
- Primary Completion
- 2026-08-31
- Completion
- 2026-08-31
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Ketamine for Low Mood States in the ER
NCT01209845 ·Status: COMPLETED ·Phase: PHASE1
-
Ketamine in Borderline Personality Disorder
NCT03395314 ·Status: TERMINATED ·Phase: PHASE2
-
Effect of Ketamine on Laboratory-induced Stress in Healthy Subjects
NCT04173962 ·Status: COMPLETED ·Phase: PHASE2
-
The Effect of Intravenous Ketamine on Non Suicidal Self Injuries.
NCT04242914 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Ketamine for Methamphetamine Use Disorder
NCT06496750 ·Status: RECRUITING ·Phase: PHASE2
-
Ketamine Therapy Experiential Education Study
NCT05468047 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
A Study to Investigate the Different Modes of (S) Ketamine Administration in Healthy Participants
NCT03808259 ·Status: COMPLETED ·Phase: PHASE1
-
Nitrous Oxide- Suicidal Ideation
NCT03736538 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1
-
Ketamine IV Classic Protocol : Five Years Follow up
NCT04824157 ·Status: COMPLETED
-
Examining The Effect Of Ketamine On Glutamate/Glutamine Cycling
NCT02037035 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Characterization of the Prosocial and Prosexual Effects of GHB
NCT02342366 ·Status: COMPLETED ·Phase: NA
-
Study of 3,4-Methylenedioxymethamphetamine-assisted Psychotherapy in People With Posttraumatic Stress Disorder
NCT00353938 ·Status: COMPLETED ·Phase: PHASE2
-
Ketamine Versus Haloperidol for Severe Agitation Outside the Hospital
NCT02103881 ·Status: WITHDRAWN ·Phase: PHASE4
-
Rapid Agitation Control With Ketamine in the Emergency Department
NCT03375671 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating Ketamine and Psychological Sequelae
NCT04053400 ·Status: COMPLETED
-
Psychopharmacological Treatment of Emotional Distress
NCT06133114 ·Status: RECRUITING ·Phase: PHASE4
-
Effectiveness of Amantadine Hydrochloride for Treatment of Severe Traumatic Brain Injury (TBI)
NCT00970944 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Low Dose Ketamine Intra Nasal Traumatology
NCT03233035 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Pharmacokinetics of GH002 in Healthy Volunteers
NCT05753956 ·Status: COMPLETED ·Phase: PHASE1
-
Ketamine-Induced Brain Changes and Their Modulation by Lamotrigine
NCT04156035 ·Status: COMPLETED ·Phase: NA
-
Additional MDMA-assisted Therapy for People Who Relapsed After MDMA-assisted Therapy Trial
NCT01458327 ·Status: COMPLETED ·Phase: PHASE2
-
Amantadine for the Treatment of Traumatic Brain Injury Irritability and Aggression: A Multi-site Study
NCT00779324 ·Status: COMPLETED ·Phase: NA
-
Safety of GH001 in Healthy Volunteers
NCT04640831 ·Status: COMPLETED ·Phase: PHASE1
-
THC and Ketamine Effects in Humans: Relation to Neural Oscillations and Psychosis
NCT04199468 ·Status: COMPLETED ·Phase: PHASE1
-
PsiloIMAGINE: A Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm
NCT06798636 ·Status: RECRUITING ·Phase: EARLY_PHASE1